HCC
Conditions
Interventions
Control group:Conventional TACE (Transfemoral artery puncture + epirubicin 40mg perfusion + lipiodol 3-5ml embolization)
Experimental group:Conventional TACE + oral apatinib mesylate (500mg po qd, adjusted to 250-750mg po qd based on tolerance
treatment interruption <30 days)
Sponsors
General Hospital of the Western Theater Command of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Pathologically or clinically diagnosed with primary liver cancer; 3. CNLC stage IIb, IIIa and partial IIIb, Child-Pugh class A/B, ECOG PS 0-2; 4. Eligible for TACE treatment; 5. No surgical indication or refusal of surgical treatment; 6. No prior radiotherapy, chemotherapy, surgery or interventional therapy for liver cancer; 7. Estimated survival time >3 months; 8. Signed informed consent form
Exclusion criteria
Exclusion criteria: 1. CNLC stage Ia, Ib, IIa, partial IIIb and IV; 2. Contraindications to TACE; 3. Severe coagulation disorders; 4. Severe cardiac, pulmonary, hepatic or renal insufficiency; 5. Severe hepatoportal shunt or hepatohepatic venous shunt; 6. Allergy to apatinib or contrast medium; 7. Distant metastasis; 8. Pregnant or lactating women; 9. History of mental illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary surgical resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR); | — |
Countries
China
Contacts
Public ContactLuo Zhulin
Western Theater Command General Hospital of the Chinese People's Liberation Army
Outcome results
None listed